Maximum Retail Prices of Medicines
.png)
.png)
Welcome to the official website of the National Medicine Regulatory Authority of Sri Lanka. We are dedicated to ensuring the safety and efficacy of medicines for the people of Sri Lanka.
The National Medicine Regulatory Authority of Sri Lanka is committed to ensuring the safety, efficacy, and quality of medicines in the country. We strive to protect public health by regulating the manufacturing, importation, distribution, and sale of medicines.
NMRA regulates medicines, medical devices, borderline products imported to and manufactured in Sri Lanka. We also regulate pharmacies. Clinical trials conducted in Sri Lanka are also regulated by us.
Find Out MoreNational Medicines Quality Assuarance of the NMRA is responsible for the analyzing of the quality of any medicine, medical device or borderline product forwarded by the Authority. It functions as an additional approved analyst when the circumstance so requires.
Find Out MorePharmacovigilance Division is responsible for monitoring and dealing with adverse drug reaction, quality failure and counterfeit medicines.
Find Out MoreInspectorate and Enforcement Division is responsible for inspecting and investigating issues pertaining to proper implementation of the provision of the NMRA Act.
Find Out MoreNational Medicines Regulatory Authority,
State Engineering Corporation Building (2nd Floor),
No. 130,
W.A.D Ramanayaka Mawatha,
Colombo 02,
Sri Lanka
To: All Market Authorization Holders
Please be informed that the Pricing Division of the National Medicines Regulatory Authority (NMRA) will implement a revised schedule for public days related to pricing regulation matters, effective from 1st April 2026.
The designated public days will be as follows:
Please note that the online appointment system will no longer be in effect. All interested parties may visit on the above-mentioned days and are required to mark their presence at the registry with the security officers at NMRA.
All stakeholders are kindly requested to plan their visits accordingly.
Chief Executive Officer
National Medicines Regulatory Authority (NMRA)
The National Medicines Regulatory Authority (NMRA) invites quotations from qualified legal professionals to provide Legal Consultation Services for a period of three (03) months,commencing from 01 st May 2026.
Calling for public hearing for Medicine Regulation.
The National Medicines Regulatory Authority (NMRA) will conduct a public hearing to obtain views, comments and recommendations from stockholders and the general public regarding the proposed Medicine Regulation.This hearing aims to promote transparency, inclusiveness, and stockholder participation in the policy-making process related to the regulation, safety,quality, and accessibility of medicines in Sri Lanka.
Healthcare professionals, industry represtatives, civil society organizations, academics and members of the public are invited to share their views and suggestions to improve the proposed policy. The feedback received during this consultation will be taken into consideration in the finalization of the Regulation.
As per the request of the above parties the authority decided to extend the time period. Therefore, the final date for the submission of feedback is 2026.04.21.
Written comments or feedback should be submitted to the following email. lo@nmra.gov.lk
Registered Post: Chief Executive Officer, National Medicines Regulatory Authority, State Engineering Corporation Building (2nd Floor), No. 130,W.A.D.Ramanayaka Mawatha, Colombo 02.
All references should be clearly stated as 'Public Comments regarding Medicine Regulation' the subject or in the top left corner of the envelope.
Please contact below for further information:
Telephone: 0112698896/7 email: lo@nmra.gov.lk
Click Here : Public hearing on the proposed Medicine Regulation
Average US Dollar Rate April-2026 for Price Approvals of MRP’s by NMRA
Notice to all Authorized Local Agents,
This is to kindly inform all authorized local agents that the USD rate considered for the month of April -2026 for processing price details of medicines/ medical devices is 313.36.
Please ensure that all price submissions for MRP approvals are prepared accordingly.
All applicants submitting Re-Registration (RR) dossiers to the National Medicines Regulatory Authority are hereby informed that a Declaration of the Product must be submitted along with the application, with effect from 1st April 2026.
Applicants are required to confirm that:
or
A standard declaration format is attached to this notice. Applicants are required to duly complete and sign the declaration by the authorized signatory of the Marketing Authorization Holder (MAH) and submit it together with the RR dossier.
Click Here : standard declaration format
